inVentiv Health, a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market, today announced the launch of two global Site Advisory Groups (SAGs). These activities are part of the company's commitment to enhanced collaboration with investigative sites, who are essential partners in trial success.
"Clinical trial sites are on the forefront of successful trials. Recognizing this, we're bringing clinical trial stakeholders together to create more innovative approaches to trial development. By working directly with sites, we can better address the challenges they face and leverage their rich insights," said Susan Stansfield, Ph.D., executive vice president, Site Centricity Unit, Clinical Division. "This increased collaboration will allow us to enhance site resource offerings."
The goal of the inVentiv-hosted SAGs is to serve as forums to pinpoint key areas for improvement in the critical study start-up phase where incremental changes can have a significant impact on overall trial results. These SAGs, which will include global representation, include:
Leaders from inVentiv Health's Site Centricity Unit (SCU) will explore ways to further collaborate with sites by leading and participating in key discussions.
The SCU, comprised of site effectiveness and efficiency experts, was created to provide focused attention and constant innovation at the site level. The group works to understand site needs and develops resources to support sites in delivering enhanced trial execution. For example, SCU has created a Site Relationship Manager who can be deployed to the most heavily utilized sites to streamline operations and uncover actionable insights.